Bristlecone Advisors’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $221K | Hold |
1,726
| – | – | 0.02% | 228 |
|
|
2025
Q2 | $209K | Buy |
+1,726
| New | +$195K | 0.02% | 218 |
|
|
2024
Q4 | – | Sell |
-1,787
| Closed | -$206K | – | 372 |
|
|
2024
Q3 | $206K | Sell |
1,787
-968
| -35% | -$110K | 0.02% | 279 |
|
|
2024
Q2 | $293K | Hold |
2,755
| – | – | 0.03% | 238 |
|
|
2024
Q1 | $266K | Hold |
2,755
| – | – | 0.02% | 247 |
|
|
2023
Q4 | $278K | Hold |
2,755
| – | – | 0.03% | 237 |
|
|
2023
Q3 | $281K | Hold |
2,755
| – | – | 0.03% | 217 |
|
|
2023
Q2 | $278K | Hold |
2,755
| – | – | 0.03% | 225 |
|
|
2023
Q1 | $253K | Sell |
2,755
-8
| -0.3% | -$699 | 0.03% | 231 |
|
|
2022
Q4 | $251K | Hold |
2,763
| – | – | 0.03% | 226 |
|
|
2022
Q3 | $210K | Hold |
2,763
| – | – | 0.03% | 232 |
|
|
2022
Q2 | $234K | Hold |
2,763
| – | – | 0.03% | 219 |
|
|
2022
Q1 | $242K | Hold |
2,763
| – | – | 0.03% | 209 |
|
|
2021
Q4 | $242K | Hold |
2,763
| – | – | 0.03% | 207 |
|
|
2021
Q3 | $226K | Hold |
2,763
| – | – | 0.03% | 204 |
|
|
2021
Q2 | $252K | Sell |
2,763
-18,630
| -87% | -$1.66M | 0.03% | 190 |
|
|
2021
Q1 | $1.83M | Sell |
21,393
-3,010
| -12% | -$270K | 0.28% | 83 |
|
|
2020
Q4 | $2.3M | Buy |
24,403
+160
| +0.7% | +$14K | 0.37% | 68 |
|
|
2020
Q3 | $2.11M | Sell |
24,243
-7,554
| -24% | -$654K | 0.38% | 67 |
|
|
2020
Q2 | $2.78M | Sell |
31,797
-95
| -0.3% | -$8.2K | 0.56% | 47 |
|
|
2020
Q1 | $2.63M | Sell |
31,892
-745
| -2% | -$66.5K | 0.63% | 38 |
|
|
2019
Q4 | $3.09M | Buy |
32,637
+1,159
| +4% | +$104K | 0.62% | 44 |
|
|
2019
Q3 | $2.73M | Sell |
31,478
-724
| -2% | -$65K | 0.67% | 41 |
|
|
2019
Q2 | $2.94M | Sell |
32,202
-5,476
| -15% | -$463K | 0.7% | 40 |
|
|
2019
Q1 | $3.25M | Buy |
37,678
+450
| +1% | +$36.1K | 0.91% | 26 |
|
|
2018
Q4 | $2.86M | Sell |
37,228
-178
| -0.5% | -$13.9K | 0.86% | 28 |
|
|
2018
Q3 | $2.89M | Buy |
37,406
+16,121
| +76% | +$1.19M | 0.73% | 38 |
|
|
2018
Q2 | $1.44M | Sell |
21,285
-3,102
| -13% | -$214K | 0.48% | 57 |
|
|
2018
Q1 | $1.77M | Sell |
24,387
-10,147
| -29% | -$772K | 0.59% | 45 |
|
|
2017
Q4 | $2.6M | Buy |
34,534
+40
| +0.1% | +$3.02K | 0.82% | 34 |
|
|
2017
Q3 | $2.65M | Buy |
34,494
+580
| +2% | +$43.8K | 0.86% | 34 |
|
|
2017
Q2 | $2.54M | Buy |
33,914
+524
| +2% | +$37.1K | 0.86% | 35 |
|
|
2017
Q1 | $2.22M | Buy |
33,390
+2,188
| +7% | +$146K | 0.78% | 40 |
|
|
2016
Q4 | $2.04M | Sell |
31,202
-2,194
| -7% | -$142K | 0.73% | 41 |
|
|
2016
Q3 | $2.36M | Sell |
33,396
-151
| -0.5% | -$11K | 0.85% | 31 |
|
|
2016
Q2 | $2.48M | Buy |
33,547
+3,460
| +11% | +$239K | 0.92% | 36 |
|
|
2016
Q1 | $1.95M | Buy |
30,087
+3,108
| +12% | +$211K | 0.77% | 43 |
|
|
2015
Q4 | $2.08M | Buy |
+26,979
| New | +$2.14M | 0.88% | 31 |
|
Other funds holding NVS
Bristlecone Advisors's NVS Position: Q3 2025 in Review
Bristlecone Advisors held its Novartis (NVS) position steady in Q3 2025 at 1,726 shares worth $221K. The position accounts for 0.02% of the portfolio, ranked #228.
Bristlecone Advisors first reported a position in NVS in Q4 2015 and has held it in 38 quarters since. The position peaked at $3.25M in Q1 2019. 1,400 funds tracked by Wall St. Rank hold NVS as of Q3 2025.
- Bristlecone Advisors held 1,726 shares of Novartis worth $221K as of Q3 2025.
- Bristlecone Advisors left its Novartis share count unchanged in Q3 2025.
- Novartis made up 0.02% of Bristlecone Advisors's portfolio in Q3 2025, its #228 holding.
- Bristlecone Advisors first reported a position in Novartis in Q4 2015 and has held it in 38 quarters since.
- Bristlecone Advisors's Novartis position peaked at $3.25M in Q1 2019.
- 1,400 funds tracked by Wall St. Rank held Novartis as of Q3 2025.
Based on Bristlecone Advisors's 13F filing for Q3 2025, filed 24 Oct 2025.